Advancing Clinical Biomarkers through Mass Spectrometry-based Discovery Proteomics

Evaluation of the thousands of proteins that comprise the human proteome and their post-translational modifications (PTMs) provides critical insight into cellular physiology and disease mechanisms that cannot be fully inferred from genomic data alone. Mass spectrometry proteomics is an ideal approach for such studies.

However, interrogation of the human proteome has been precluded to date by the lack of robust bioanalytical systems that enable comprehensive measure of diverse proteins, PTMs, and protein variants in complex human biosamples, including blood, with high throughput.

In this webinar hosted by AAPS, we discuss next-generation bioanalytical systems for proteomics studies in humans. We focus on high throughput, ‘discovery’ mass spectrometry proteomics as an analytical solution that now enables accurate and robust measure of thousands of proteins across thousands of individuals. This approach provides highly accurate protein identification and PTM information at scale.

We specifically cover how discovery mass spectrometry proteomics:

• Uses nanoLC coupled to trapped ion mobility mass spectrometry and nanoparticle enrichment to measure thousands of proteins across diverse bioanalytical pathways.
• Provides high analytical specificity via direct peptide measure, and with capture of PTMs to allow for more in-depth analysis of protein function and regulation.
• Compares and contrasts to affinity-based binding proteomics technologies and other mass spectrometry-based approaches.
• Allows for scalable coverage in diverse liquid and tissue matrices (plasma, cells, and tissue).
• Generates data that can be integrated with other omics information to more fully interrogate disease and drug response across individuals.

You’ll learn how Sapient’s high throughput, mass spectrometry proteomics method is transforming the depth and efficiency at which we can measure the blood and tissue proteome to extract greater biological insight.